This meeting report presents the outcomes of a workshop held in Bangkok on December 1st 2014, where the following challenges were discussed: the threat of resistance to artemisinin and artemisinin-based combination therapy in the Greater Mekong Sub-region (GMS) and in Africa; access to treatment for most at risk and hard to reach population; insecticide resistance, residual and outdoors transmission.
The present data do not suggest widespread artemisinin resistance in Dakar in 2012-2013.
The CRIMALDDI Consortium has been a three-year project funded by the EU Framework Seven Programme.
The parasites responsible for artemisinin-resistant malaria in a clinical trial in Western Cambodia comprise the dominant clones of acute malaria infections rather than minority clones emerging during treatment.
Resistance to artemisinin casts a shadow on the fight against malaria.
An increased artemisinin-resistant phenotype occurs along with a mutation in a functional element of the AP2 adaptor protein complex.
Taken together, the results suggest, in particular, that pfatpase6 S769N gene needs more consideration for its possible association with artesunate resistance among P. falciparum isolates.